Disease · EFO_1001458
diabetic cardiomyopathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. diabetic cardiomyopathy. Diseases, record EFO_1001458. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001458
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CAFICRESTAT | CHEMBL4297455 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| RESAMIRIGENE BILPARVOVEC | CHEMBL4298181 | Gene | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TRIMETAZIDINE | CHEMBL203266 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZINC ACETATE | CHEMBL3184986 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACIPIMOX | CHEMBL345714 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIRAGLUTIDE | CHEMBL4084119 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AKR1B1 | Aldo-keto reductase family 1 member B1 | 1 | Aldose reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/231 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 1 | Glucagon-like peptide 1 receptor agonist | Unknown | https://conductscience.org/library/genes/2740 | Drugs and targets |
Trials5
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00696410 | The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy | Phase 1 | 48 | 2017-10-04 | Heart Failure, Cardiomyopathies | ZINC ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT04083339 | Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Phase 3 | 675 | Diabetic Cardiomyopathies | CAFICRESTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT05556005 | Efficacy of Trimetazidine in Diabetic Patients | Phase 2 | 60 | Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies | TRIMETAZIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03498001 | Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging | Not applicable | 42 | Type II Diabetes | LIRAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00943059 | Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function | Not applicable | 31 | Diabetes Mellitus, Type 2, Cardiomyopathy, Dilated | ACIPIMOX | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| HF Group vs Healthy Controls: deaths from any cause | 0 of 38 | 0 of 10 | 48 | NCT00696410 | Trial comparisons |
| HF Group vs Healthy Controls: serious adverse events | 3 of 38 | 0 of 10 | 48 | NCT00696410 | Trial comparisons |
Papers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39900263 | RESULT | 1 | PubMed |
| 42538062 | DERIVED | 1 | PubMed |
| 40338768 | DERIVED | 1 | PubMed |
| 40315802 | DERIVED | 1 | PubMed |
| 39882614 | DERIVED | 1 | PubMed |
| 39814796 | DERIVED | 1 | PubMed |
| 39806375 | DERIVED | 1 | PubMed |
| 39095808 | DERIVED | 1 | PubMed |
| 38986667 | DERIVED | 1 | PubMed |
| 38597864 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001458
GET https://conductscience.org/api/diseases/v1/EFO_1001458/drugs